Recent studies have highlighted the multifaceted role of KRAS mutations in tumor biology—not only do they intrinsically promote tumorigenesis, but they also modulate the immune microenvironment by driving the production of immunosuppressive cytokines and chemokines through downstream signaling pathways [57]. The gene discussed is KRAS; the disease is neoplasm.